12/03/2026
💥The main requirements for a Scleroderma patient to qualify for a Stem Cell Transplant, specifically
💥Autologous Hematopoietic Stem Cell Transplantation (AHSCT) — the only stem-cell approach currently recommended in major rheumatology guidelines.
💥 Main Updated Requirements
For Scleroderma Patients to Qualify for Stem Cell Transplant (AHSCT)
Stem cell transplant is not suitable for most patients.
It is recommended only for carefully selected patients with severe disease but without irreversible organ failure.
Major guidelines agree on the following criteria.
1️⃣ Diagnosis of Severe Systemic Sclerosis
The patient must have confirmed systemic sclerosis (SSc), usually :
• Diffuse cutaneous systemic sclerosis (dcSSc)
• Rapidly progressive disease
• Early disease stage
Patients with limited cutaneous SSc are usually not candidates.
Why :
Because clinical trials showed the benefit mainly in diffuse early aggressive disease.
Evidence :
* ASTIS trial
* SCOT trial
* EBMT registry data
2️⃣ Early Disease Duration (Usually < 5 Years)
Most transplant programs require:
Disease duration :
typically ≤ 5 years since first non-Raynaud symptom
Why this matters :
The transplant works by resetting the immune system before irreversible fibrosis occurs.
Patients with long-standing fibrosis often do not benefit.
3️⃣ Evidence of Rapid Disease Progression
Patients must show active and worsening disease, such as :
Examples :
• Rapidly worsening skin thickening
• Increasing modified Rodnan Skin Score (mRSS)
• Progressive interstitial lung disease (ILD)
• Declining lung function (FVC or DLCO)
Typical indicators:
• FVC drop >10%
• DLCO decline
• worsening fibrosis on HRCT
📚 Source
Major transplant trials and transplant guidelines.
4️⃣ Failure or Inadequate Response to Standard Therapy
Patients usually must have failed or not responded adequately to conventional immunosuppressive therapy, such as :
• Cyclophosphamide
• Mycophenolate mofetil
• Methotrexate
• Biologic therapy (sometimes)
Stem cell transplant is considered a high-risk rescue therapy.
📚 Source
EULAR systemic sclerosis treatment guidelines.
5️⃣ No Advanced Cardiac Disease
This is the most important safety screening step.
Patients cannot receive transplant if they have severe heart involvement.
Typical exclusion criteria include :
• Left ventricular ejection fraction 50 mmHg
Severe PAH significantly increases transplant mortality.
📚 Source
Transplant eligibility studies and safety protocols.
7️⃣ Adequate Lung Function
Minimum lung function usually required:
Typical criteria used in transplant programs:
• DLCO > 40% predicted
• Acceptable oxygenation
Patients with end-stage lung disease are generally excluded.
📚 Source
Transplant registry studies.
8️⃣ Adequate Kidney Function
Typical requirement:
• Creatinine clearance >40–50 mL/min
Patients with :
• severe renal failure
• active scleroderma renal crisis
are usually not eligible.
9️⃣ No Active Infection
Because transplant causes profound immune suppression, patients must not have :
• active infections
• uncontrolled viral infections
• sepsis
🔟 Acceptable Age and General Health
Most programs use approximate limits:
Typical :
• Age 18–65 years (sometimes up to 70 in specialized centers)
Patients must have :
• good functional status
• ability to tolerate chemotherapy
1️⃣ Treatment Must Be Done in a Specialized Transplant Center
Guidelines emphasize that AHSCT should be performed only in:
• experienced centers
• multidisciplinary teams (rheumatology + hematology)
📚 Source
* British Society for Rheumatology 2024 guideline.
Important Reality About Stem Cell Transplant in Scleroderma
Even when patients qualify:
Risk of transplant-related death:
~3–10% depending on center experience
However major trials show :
Benefits may include :
• improved survival
• reduced skin fibrosis
• stabilization of lung disease
📚 Evidence trials
* ASTIS trial
* SCOT trial
* EBMT registry
# Simplified Summary
A patient may qualify if they have :
✔ Early aggressive diffuse scleroderma
✔ Rapid disease progression
✔ Failure of standard treatment
✔ Good heart function
✔ No severe pulmonary hypertension
✔ Lung function not severely damaged
✔ Adequate kidney function
✔ No active infection
✔ Age generally
The British Society for Rheumatology has updated its 2015 guidelines for the management of patients with systemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
